Sarah A. Reda

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d2a5b100-504e-11ef-931e-8373c6b518fb.jpg

First Name

Sarah

Last Name

Reda

NPI

1003304510

Faculty ID

17794

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

186405

Visit Type ID

2499

Is Open Scheduling

On

Jamie L. Osman-Wager

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/99faf9c0-f4ea-11ed-b165-5b052597da41.jpg

First Name

Jamie

Last Name

Osman-Wager

NPI

1093006652

Faculty ID

14779

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Adult Medicine<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

52406

Biography

<p>Jamie Osman-Wager, MD, MPH, is an attending physician and Assistant Professor, Medicine at Montefiore Einstein. Her clinical focus centers on adult medicine.</p><p>After obtaining her Bachelor of Science from Cornell University in 2005, Dr. Osman-Wager completed a dietetic internship at NewYork-Presbyterian Hospital in 2006. She continued her medical education, earning her Master of Public Health at Harvard in 2010 and her Doctor of Medicine at Montefiore Einstein in 2011. She completed her internal medicine residency at New York University Langone Medical Center in 2014.</p><p>Dr. Osman-Wager&rsquo;s research has been published in numerous peer-reviewed journals and presented at national conferences. She currently serves as site leader at Montefiore Einstein&rsquo;s Moses campus for the third year medical student internal medicine clerkship. Most of her time focuses on educating and training residents and medical students.</p><p>Dr. Osman-Wager is board certified in Internal Medicine and is a member of the American Board of Internal Medicine and the Medical Society of the State of New York. In 2021, she won the Leo M. Davidoff Society Award for Excellence in the Teaching of Medical Students.</p>

Is Open Scheduling

On

Sriram Machineni

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c68653a0-bec9-11ee-aa99-759018b444d6.jpg

First Name

Sriram

Last Name

Machineni

NPI

1750350666

Faculty ID

17510

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni obtained his medical degree from the All India Institute of Medical Sciences in New Delhi, followed by a residency in internal medicine at the State University of New York at &nbsp;Buffalo. He served as chief resident and primary care teaching physician at Buffalo General Hospital. He subsequently completed a clinical and research fellowship in obesity medicine and metabolism at Massachusetts General Hospital/ Harvard Medical School and stayed on as an instructor. Dr. Machineni studied energy balance and body fat regulation in animal models allowing the interpretation of clinical research findings and phenotypes in the context of physiology.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni moved to the University of North Carolina at Chapel Hill (UNC) to start a clinical obesity program for treatment, education, and pharmaceutical clinical obesity trials. During his term at UNC, he helped create an obesity primary care network in central North Carolina. He was recruited to Montefiore Medical Center to develop a new medical obesity program.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">The Fleischer Institute Medical Weight Center at Montefiore Einstein, founded by Dr. Machineni, is designed to support clinical, educational, and research endeavors in the field of obesity medicine. The program leverages individual variations in response to treatments and uses multiple modalities for weight reduction to treat the comorbidities of obesity and improve quality of life. Special programs are available for individuals who need to lose weight to quality for medical and surgical procedures. The Medical Weight Center works closely with the Montefiore bariatric surgery program to offer a broad spectrum of treatment modalities.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">Dr. Machineni has clinical expertise in the m</span><span style="font-family: Calibri, sans-serif; font-size: 12pt;">ultidisciplinary management of obesity, anti-obesity medications, and post-bariatric medical complications, including nutritional deficiencies, hypoglycemia, weight regain, malabsorption, and diarrhea. He</span><span style="font-family: Calibri, sans-serif;">&nbsp;is among a handful of physicians in the New York area with Castle Connolly Top Doctors designation in obesity medicine.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p>1: Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H,Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; <strong>SURMOUNT-2 investigators</strong>.Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi:10.1016/S0140-6736(23)01200-X. Epub ahead of print. PMID: 37385275.</p>
<p>2: Pagidipati NJ, Mulder H, Chiswell K, Lampron Z, Jones WS, <strong>Machineni S</strong>,Waitman LR, Mongraw-Chaffin M, Waterman F, Kumar N, Ramasamy A, Smolarz G,Peterson ED, O'Brien E. Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity. PrevMed. 2023 May;170:107496. doi:10.1016/j.ypmed.2023.107496. Epub 2023 Mar 29.PMID: 36997096.</p>
<p>3: Ro SJ, Lackey AR, Aymes SE, McCauley JL, Davis TC, Wang R, Stanley W, Ratner SP, <strong>Machineni S</strong>, Fiscus LC. Impact of a Community-Based Weight Management Program in a North Carolina Health Care System. Fam Med. 2023 Mar;55(3):189-194.doi: 10.22454/FamMed.2023.603918. Epub 2023 Jan 31. PMID: 36888674.</p>
<p>4: Aronne LJ, Bramblette S, Ingelfinger JR, Jastreboff AM, <strong>Machineni S,</strong> Massie N, Rosen CJ. When Weight Impacts Health. N Engl J Med. 2023 Jan 12;388(2):e2. doi: 10.1056/NEJMp2215794. PMID: 36630621.</p>
<p>5: Aronne LJ, Bramblette S, Huett-Garcia A, Ingelfinger JR, Jastreboff AM, <strong>Machineni S</strong>, Massie N, Rosen CJ. Weight and Health - Pathophysiology and&nbsp;Therapies. N Engl J Med. 2022 Dec 15;387(24):e62. doi: 10.1056/NEJMp2214423. PMID: 36516089.</p>
<p>6: le Roux CW, Zhang S, Aronne LJ, Kushner RF, Chao AM, <strong>Machineni S</strong>, Dunn J, Chigutsa FB, Ahmad NN, Bunck MC. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2023 Jan;31(1):96-110. doi: 10.1002/oby.23612. Epub 2022 Dec 7. PMID: 36478180; PMCID: PMC10107501.</p>
<p>7: Bionic Pancreas Research Group; Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K,Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB,Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, Forlenza G, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, <strong>Machineni S</strong>, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172. doi: 10.1056/NEJMoa2205225. PMID: 36170500; PMCID: PMC10028490.</p>
<p>8: Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, <strong>Machineni S</strong>, Varbo A,Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism andGlycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg AmongParticipants With Prediabetes in the STEP Program. Diabetes Care. 2022 Oct1;45(10):2396-2405. doi: 10.2337/dc21-1785. PMID: 35724304; PMCID: PMC9862484.</p>
<p>9: Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A,Zhang S, Liu B, Bunck MC, Stefanski A; <strong>SURMOUNT-1 Investigators</strong>. TirzepatideOnce Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.</p>
<p>10: Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, Buse JB, Valcarce C;<strong>SimpliciT1 research group</strong>. The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. Diabetes Care. 2021 Apr;44(4):960-968. doi:10.2337/dc20-2684. Epub 2021 Feb 23. PMID:33622669; PMCID: PMC7985421.</p>
<p>11: Melanie Davies, Louise F&aelig;rch, Ole K Jeppesen, Arash Pakseresht, Sue D Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A Wadden, Ildiko Lingvay; <strong>STEP 2 Study Group</strong>.&nbsp; Semaglutide 2&middot;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. PMID: 33667417.</p>
<p>12: Rosman L, Armbruster T, Kyazimzade S, Tugaoen Z, Mazzella AJ, Deyo Z, Walker J, <strong>Machineni S,</strong> Gehi A. Effect of a virtual self-management intervention for atrial fibrillation during the outbreak of COVID-19. Pacing Clin Electrophysiol. 2021 Mar;44(3):451-461. doi: 10.1111/pace.14188. Epub 2021 Feb 17. PMID: 33565642; PMCID: PMC8014277.</p>
<p>13: Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; <strong>STEP 3 Investigators.</strong> Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Feb 24. PMID: 33625476; PMCID: PMC7905697.</p>
<p>14: Jensen SM, Thompson RE, <strong>Machineni S,</strong> Overby DW, Farrell TM. Refractory Hypocalcemia Following Stomach Intestinal Pylorus-Sparing Bariatric Surgery and Thyroidectomy: Successful Management With Creation of a Proximal Roux-en-Y Gastric Bypass. Am Surg. 2021 Apr;87(4):576-580. doi: 10.1177/0003134820952427. Epub 2020 Oct 30. PMID: 33125276.</p>
<p>&nbsp;</p>
<p>15: Kushner RF, Batsis JA, Butsch WS, Davis N, Golden A, Halperin F, Kidambi S, <strong>Machineni S,</strong> Novick M, Port A, Rubino DM, Saunders KH, Shapiro Manning L, Soleymani T, Kahan S. Weight History in Clinical Practice: The State of the Science and Future Directions. Obesity (Silver Spring). 2020 Jan;28(1):9-17. doi: 10.1002/oby.22642. PMID: 31858735.</p>
<p>16: Kushner RF, Butsch WS, Kahan S, <strong>Machineni S,</strong> Cook S, Aronne LJ. Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested? Teach Learn Med. 2017 Apr-Jun;29(2):123-128. doi:10.1080/10401334.2016.1250641. Epub 2016 Dec 29. PMID: 28033472.</p>
<p>17: Carmody JS, Ahmad NN, <strong>Machineni S,</strong> Lajoie S, Kaplan LM. Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice. Endocrinology. 2015 Sep;156(9):3183-91. doi: 10.1210/en.2015-1226. Epub 2015 Jun 11. PMID: 26066076; PMCID: PMC4541621.</p>
<p>18: Liou AP, Paziuk M, Luevano JM Jr, <strong>Machineni S,</strong> Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013 Mar 27;5(178):178ra41. doi:10.1126/scitranslmed.3005687. PMID: 23536013; PMCID: PMC3652229.</p>
<p>19: Bose M, Teixeira J, Olivan B, Bawa B, Arias S, <strong>Machineni S,</strong> Pi-Sunyer FX, Scherer PE, Laferr&egrave;re B. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010 Mar;2(1):47-55. doi: 10.1111/j.1753-0407.2009.00064.x. PMID: 20676394; PMCID: PMC2910618.</p>
<p>20: Bose M, <strong>Machineni S,</strong> Oliv&aacute;n B, Teixeira J, McGinty JJ, Bawa B, Koshy N, Colarusso A, Laferr&egrave;re B. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring). 2010 Jun;18(6):1085-91. doi: 10.1038/oby.2009.473. Epub 2010 Jan 7.PMID: 20057364; PMCID: PMC2877144.</p>

EMR ID

179058

Is Open Scheduling

Off

Hauchie Pang

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/7f1d02d0-ee0c-11ee-904c-09056fc0ef1f.jpg

First Name

Hauchie

Last Name

Pang

NPI

1093161499

Faculty ID

16544

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Adult Medicine<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

87585

Is Open Scheduling

Off

Beatrice Y. Wong

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b4012680-c3c5-11eb-9ea2-7374238588d1.jpg

First Name

Beatrice

Last Name

Wong

NPI

1033656541

Faculty ID

16257

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

95560

Visit Type ID

2499

Is Open Scheduling

On

Rebecca A. Williams

https://assets.montefioreeinstein.org/profiles/images/10077-rebecca-williams.jpg

First Name

Rebecca

Last Name

Williams

NPI

1841375979

Faculty ID

10077

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Education</strong></p>
<p>Medical School: University of Illinois at Chicago (UIC)<br />Residency: University of Wisconsin, Appleton</p>
<p><strong>Professional Activity</strong></p>
<p>Dr. Rebecca Williams specializes in Family Medicine with concentrated practice in maternity care. She returned to UIC as residency faculty coordinating women&rsquo;s health training. She completed a faculty development fellowship and a master's degree in health professions education. In 2004, she joined the Montefiore Einstein Department of Family and Social Medicine as residency faculty. She currently serves as the Director of Maternity Services for Family Medicine. After years as the sole attending family physician delivering babies at Montefiore hospitals, she now leads a team of family physicians providing care to a large group of women.</p>
<p>Dr. Williams holds an academic appointment in the Department of Family and Social Medicine. She is a member of the Society of Teachers of Family Medicine and teaches residents, students and fellows. She supervises training of residents on labor and delivery and in the office. She directs the Fellowship in Family Centered Maternity Care.</p>
<p>Dr. Williams's research interests are medical education and women&rsquo;s health, with a focus on normal birth.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Family Medicine

Elsevier Profile

Selected Publications

<ol>
<li>Schonberg, D and Williams, RA. Physical Activity in Pregnancy. What Should the Family Physician Recommend? Family Doctor. A Journal of the New York State Academy of Family Physicians. Winter 2013; 2(3):20-2.</li>
<li>NYMC Phelps Family Medicine Residency. AAFP Recommended Curriculum for Family Medicine Residency. Reprint 289C. Practice Based Learning and Improvement. Revised 7/2012.</li>
<li>Williams, RA. Women&rsquo;s Health Content Validity of the Family Medicine In-training Examination. Family Medicine 2007;39:572-7.</li>
<li>Williams RA, Elam G: Gynecology in Rakel RE (Ed.): Textbook of Family Practice, Seventh Edition. Saunders, Philadelphia, 2007.</li>
<li>Williams RA: Breast-feeding in Rakel RE (Ed.): Saunders Manual of Medical Practice, Second Edition. Saunders, Philadelphia, 2000.</li>
<li>Hannon PR, Ehlert-Abler P, Aberman S, Williams RA, Carlos M. Commentary: A Multidisciplinary Approach to Promoting a Baby Friendly Environment in an Urban University Medical Center. Journal of Human Lactation 1999;15:289-296.</li>
</ol>

EMR ID

4657

Biography

<p>Rebecca Williams, MD, MHPE , FAAFP, is Director, Maternity Services and Assistant Professor at Montefiore Einstein. Dr. Williams has more than three decades of experience as a family physician.</p><p>After completing her undergraduate education at the University of Illinois at Urbana-Champaign, Dr. Williams earned her Doctor of Medicine at the University of Illinois at Chicago. She began her postgraduate training in Wisconsin with an internship at Southeastern Family Practice, followed by a residency at Appleton Family Practice.</p><p>Dr. Williams is a Fellow of the American Academy of Family Physicians and a member of the Society of Teachers of Family Medicine.</p>

Is Open Scheduling

On

Kristen Welch

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/f668ba00-91b5-11ed-bc46-2f7b4c1ecd09.jpg

First Name

Kristen

Last Name

Welch

NPI

1609220623

Faculty ID

16736

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Adult Medicine<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

122812

Is Open Scheduling

On

Jeffrey M. Weiss

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/56918540-eabd-11ee-964a-bb8efcf16059.jpg

First Name

Jeffrey

Last Name

Weiss

NPI

1841375623

Faculty ID

9980

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Jeffrey Weiss, MD is a senior clinician-executive who has taken on progressive leadership positions at Montefiore Health System. Dr. Weiss earned a bachelor of science in industrial and labor relations from Cornell University, a medical degree from Stony Brook School of Medicine, and the Internal Medicine Residency Program at Montefiore, where he was chief resident.</p>
<p>In 2007, Dr. Weiss was named Institutional Medical Director for Montefiore Health System. His role is to help optimize the performance of the Montefiore health delivery network by ensuring a smooth interface between its various components - the doctors, hospital, medical group, home health agency, nursing homes, and the CMO. Dr. Weiss's responsibilities included leadership of nationally recognized patient safety, quality and peer review programs, management of a medical staff with 3,500 employed and voluntary physicians, supervision of GME activities for 1,200 residents in the second largest house staff program in the country, all under the coordinated umbrella of the "Office of the Medical Director" (OMD). As part of a restructuring of organizational clinical leadership in 2012, Dr. Weiss was named Vice President for Medical Affairs. In this role, he has retained many of his previous responsibilities, and is now leading a team of five newly appointed hospital medical directors in driving physician alignment and creating a horizontally integrated approach to quality and clinical performance across the system.</p>
<p>Dr. Weiss is an active clinician, teacher and researcher. He lectures nationally on topics including leadership, physician alignment, and patient safety in several forums, including as a faculty member for the AAMC and National Patient Safety Foundation.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Adult Medicine<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

4102

Is Open Scheduling

Off

Ryna Villar

https://assets.montefioreeinstein.org/profiles/images/physphoto/Villar_Ryna_MD_11116285.jpg

First Name

Ryna

Last Name

Villar

NPI

1639296403

Faculty ID

12726

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Languages

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Education</strong></p>
<p>Medical School: Warren Alpert Medical School of Brown University<br />Residency: New York Presbyterian Hospital</p>
<p><strong>Professional Activity</strong></p>
<p>Resident advising, medical student supervision, CQI, HIV CQI and care coordination resident teaching, inpatient medicine/resident supervision.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Family Medicine

Elsevier Profile

EMR ID

4942

Is Open Scheduling

On

Yaron Tomer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e3b1f380-8c61-11ed-9474-c3e3b839843d.jpg

First Name

Yaron

Last Name

Tomer

NPI

1982662334

Faculty ID

14884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Yaron Tomer is the Marilyn and Stanley M. Katz Dean at Albert Einstein College of Medicine and Chief Academic Officer at Montefiore Medicine.</p>
<p>He received his M.D. degree magna cum laude from the Sackler School of Medicine of Tel Aviv University and trained in Internal Medicine at Sheba Medical Center, Israel, and in Endocrinology at the Icahn School of Medicine at Mount Sinai in New York. Prior to joining Montefiore Einstein in March 2016, he was Chief of the Division of Endocrinology, Diabetes, and Bone Disease at Mount Sinai.</p>
<p>Dr. Tomer has served on the editorial boards of <em>Endocrinology </em>and <em>The Journal of Clinical Endocrinology and Metabolism</em>, among others. He is a member of the American Society for Clinical Investigation and a Fellow of the American College of Physicians. Dr. Tomer is the recipient of several prestigious awards, including the American Thyroid Association&rsquo;s Sidney H. Ingbar Distinguished Lectureship Award, as well as its Van Meter Award.</p>
<h3>Research</h3>
<p>Dr. Tomer&rsquo;s research program focuses on the immunogenetic, epigenetic, and environmental mechanisms underlying thyroid autoimmunity, and type 1 diabetes, and on targeting these mechanisms in order to develop novel therapies. His group made several discoveries including identifying new genes and mechanisms underlying the strong association between type 1 diabetes and autoimmune thyroiditis; demonstrating that CD40 and thyroglobulin are major susceptibility genes for thyroid autoimmunity; identifying a unique amino acid variant in the peptide binding pocket of HLA-DR that is key for the development of thyroid autoimmunity; dissecting the epigenetic mechanisms by which polymorphisms in the thyroglobulin and TSHR genes interact with environmental agents (e.g. viruses) to trigger thyroid autoimmunity; and identifying a novel small molecule that can block antigen presentation in autoimmune thyroiditis.</p>
<h3>Current Projects</h3>
<ol role="list">
<li><strong>Genetic and epigenetic studies in thyroid autoimmunity</strong><br />The Tomer lab mapped several susceptibility genes for autoimmune thyroid diseases (AITD) including CD40, thyroglobulin, and TSHR. Recent data suggest that variants in regulatory regions of some of these genes interact epigenetically with environmental factors (e.g., viral infections) to trigger disease. Current studies are using epigenomic screening, including whole genome methylation studies and ChiP-seq analyses to study these genetic-epigenetic interactions.</li>
<li><strong>Epigenetic studies in type 1 diabetes</strong><br />Similar studies are utilizing epigenomic screening to analyze epigenetic interactions between known type 1 diabetes susceptibility genes and interferon alpha, a key cytokine secreted during viral infections.</li>
<li><strong>Translational studies in autoimmune thyroiditis (AITD) and type 1 diabetes</strong><br />The Tomer lab discovered that the presence of arginine at position beta-74 of the peptide binding pocket of HLA-DR is critical for the development of AITD. This discovery led to a translational project aimed at blocking thyroid antigen presentation to T-cells by the arginine beta-74 HLA-DR peptide binding pocket as a potential therapy for AITD. Recently, the Tomer lab identified a small molecule, Cepharanthine, that can block antigen presentation and suppress AITD in mouse models. Similar studies are performed in type 1 diabetes where the aim is to block the HLA-DQ8 peptide binding pocket from presenting insulin peptides to T-cells as a novel strategy to treat autoimmune diabetes.</li>
<li><strong>Genetic and functional analyses of autoimmune polyglandular syndrome (APS) type 3</strong><br />The co-occurrence of type 1 diabetes and autoimmune thyroiditis in the same individual is considered a variant of the APS type 3 syndrome. The Tomer lab discovered several new susceptibility genes for APS3. The lab is now analyzing the mechanisms by which these genes predispose to disease.</li>
<li><strong>The role of viruses in triggering autoimmune thyroiditis and type 1 diabetes</strong><br />Certain infections, such as hepatitis C, are associated with autoimmune thyroiditis and diabetes. Current studies are aimed at dissecting the mechanisms by which interferon alpha, the primary cytokine secreted during viral infections, can trigger autoimmune thyroiditis and diabetes in genetically susceptible individuals.</li>
</ol>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol role="list">
<li>Menconi F, Monti MC, Greenberg DA, Oashi T, Osman R, Davies TF, Ban Y, Jacobson EM, Concepcion ES, Li CW, <span class="underline">Tomer Y</span>. Molecular amino acid signatures in the MHC class II peptide binding pocket predispose to autoimmune thyroiditis in humans and in mice. Proc Natl Acad Sci USA 2008; 105: 14034-14039.</li>
<li>Jacobson EM, Yang H, Menconi F, Wang R, Osman R, Skrabanek L, Li CW, Fadlalla M, Gandhi A, Chaturvedi V, Smith EP, Schwemberger S, Osterburg A, Babcock GF, <span class="underline">Tomer Y</span>. Employing a recombinant HLA-DR3 expression system to dissect MHC II-thyroglobulin peptide dynamism: A genetic, biochemical, and reverse immunological perspective. J Biol Chem 2009; 284: 34231-34243.</li>
<li>Villano MJ, Huber AK, Greenberg DA, Golden BK, Concepcion E, <span class="underline">Tomer Y</span>. Autoimmune thyroiditis and diabetes: Dissecting the joint genetic susceptibility in a large cohort of multiplex families. J Clin Endocrinol Metab 2009; 94: 1458-1466.</li>
<li>Menconi F, Osman R, Monti MC, Greenberg DA, Concepcion ES, <strong>Tomer Y</strong>. Shared molecular amino acid signature in the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and thyroiditis. Proc Natl Acad Sci USA 2010; 107: 16899-16903.</li>
<li>Menconi F, Huber A, Osman R, Concepcion E, Jacobson EM, Stefan M, David, CS, <span class="underline">Tomer Y</span>. Tg.2098 is a major human thyroglobulin T-cell epitope. J Autoimmun 2010; 35: 45-51.</li>
<li>Stefan M, Jacobson EM, Huber AK, Greenberg DA, Li CW, Skrabanek L, Concepcion E, Fadlalla M, Ho K, <span class="underline">Tomer Y</span>. Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J Biol Chem 2011; 286: 31168-31179.</li>
<li>Huber AK, Finkelman FD, Li CW, Concepcion E, Smith E, Jacobson E, Latif R, Keddache M, Zhang W, <span class="underline">Tomer Y</span>. Genetically driven target tissue overexpression of CD40: A novel mechanism in autoimmune disease. J Immunol 2012; 189: 3043-3053.</li>
<li>Stefan M, Wei C, Lombardi A, Li CW, Concepcion ES, Inabnet WB 3rd, Owen R, Zhang W, <span class="underline">Tomer Y</span>. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci USA 2014; 111: 12562-12567.</li>
<li><span class="underline">Tomer Y</span>, Dolan LM, Kahaly G, Divers J, D&rsquo;Agostino Jr. RB, Imperatore G, Dabelea D, Marcovina S, Black MH, Pihoker C, Hasham A, Hammerstad SS, Greenberg DA, Lotay V, Zhang W, Monti MC, Matheis N. Genome wide identification of new genes and pathways in patients with autoimmune thyroiditis and type 1 diabetes. J Autoimmun 2015; 60: 32-39.</li>
<li>Li CW, Menconi F, Osman R, Mezei M, Jacobson EM, Concepcion E, David CS, Kastrinsky DB, Ohlmeyer M, <strong>Tomer Y</strong>. Identifying a small molecule blocking antigen presentation in autoimmune thyroiditis. J Biol Chem 2016; 291: 4079-4090.</li>
<li>Li CW, Osman R, Menconi F, Concepcion ES, <span class="underline">Tomer Y</span>. Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes. J Autoimmun 2017; 76: 1-9.</li>
<li>Faustino LC, Lombardi A, Madrigal-Matute J, Owen RP, Libutti SK, <span class="underline">Tomer Y</span>. Interferon alpha triggers autoimmune thyroid diseases via lysosomal-dependent degradation of thyroglobulin. J Clin Endocrinol Metab 2018; 103: 3678-3687.</li>
<li>Stefan-Lifshitz, M, Karakose E, Cui L, Ettela A, Yi Z, Zhang W, <span class="underline">Tomer Y</span>. Epigenetic modulation of &beta;-cells by interferon-&alpha; via PNPT1-miR26a-TET2 triggers autoimmune diabetes. JCI Insight 2019; 4: e126663.</li>
<li>Li CW, Osman R, Menconi F, Concepcion E, <span class="underline">Tomer Y</span>. Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: Therapeutic implications to Graves&rsquo; disease. J Autoimmun 2020; 108: 102402.</li>
<li>Lombardi, A, Concepcion E, Hou H, Arib H, Mezei M, Osman R, <span class="underline">Tomer Y</span>. Retro-inverso D-peptides as a novel targeted immunotherapy for type 1 diabetes. J Autoimmune 2020; 115: 102543.</li>
<li>Li CW, Sachidanandam R, Jayaprakash A, Yi Z, Zhang W, Stefan-Lifshitz M, Concepcion E, <span class="underline">Tomer Y</span>. Identification of new rare variants associated with familial autoimmune thyroid diseases by deep sequencing of linked loci. J Clin Endocrinol Metab 2021; 12: 691781.</li>
<li>Ye J, Stefan-Lifshitz M, <span class="underline">Tomer Y</span>. Genetic and environmental factors regulate the type 1 diabetes gene CTSH via differential DNA methylation. J Biol Chem 2021; 296: 100774.</li>
<li>Li CW, Osman R, Menconi F, Faustino LC, Kim K, Clarke OB, Hou H, <span class="underline">Tomer Y</span>. Cepharanthine blocks presentation of thyroid and islet peptides in a novel humanized autoimmune diabetes and thyroiditis mouse model. Front Immunol 2021; 12: 796552.</li>
</ol>

EMR ID

81697

Is Open Scheduling

Off